相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vascular Endothelial Cells Produce Coagulation Factors That Control Their Growth via Joint Protease-Activated Receptor and C5a Receptor 1 (CD88) Signaling
Devin Cao et al.
AMERICAN JOURNAL OF PATHOLOGY (2022)
Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes
Zhiping Jin et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)
An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes-application to establishing CYP2C8 inhibitor selectivity
Helina Kahma et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report
Shinya Takasaki et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2020)
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Management of adverse effects/toxicity of ibrutinib
Semra Paydas
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation
Yoichi Sasaki et al.
HEPATOLOGY RESEARCH (2019)
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
Ming Zhou et al.
CANCER COMMUNICATIONS (2019)
Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species
Chen-chun Zhong et al.
ACTA PHARMACOLOGICA SINICA (2018)
Tissue factor as a mediator of coagulation and signaling in cancer and chronic inflammation
Claudine Graf et al.
THROMBOSIS RESEARCH (2018)
Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method
Wei Sun et al.
BIOMED RESEARCH INTERNATIONAL (2017)
An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s
Zhong-hua Chen et al.
ACTA PHARMACOLOGICA SINICA (2016)
A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma
William Travis Foxx-Lupo et al.
CLINICAL GENITOURINARY CANCER (2016)
Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer
Hironori Kitade et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2016)
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
Claes Held et al.
EUROPEAN HEART JOURNAL (2015)
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
Yi Gu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin
Zhen Zhang et al.
JOURNAL OF ETHNOPHARMACOLOGY (2014)
Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials
W. -X. Qi et al.
ANNALS OF ONCOLOGY (2013)
The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
Guru Sonpavde et al.
CURRENT ONCOLOGY REPORTS (2012)
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin
Laura V. Moretti et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Interspecies differences in coagulation profile
Jolanta M. Siller-Matula et al.
THROMBOSIS AND HAEMOSTASIS (2008)
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
Marcella Martignoni et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro:: kinetics and warfarin inhibition
CR Wilson et al.
TOXICOLOGY (2003)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat
K Kobayashi et al.
BIOCHEMICAL PHARMACOLOGY (2002)
分享论文
